OXFORD--Oxford Molecular Group announced it reached an agreement jointly with its associate companies, Cambridge Combinatorial and Cambridge Drug Discovery, to provide research services and consulting in drug design, combinatorial chemistry, and high-throughput screening to Oxford GlycoScience. The research program will initially target the design and synthesis of inhibitors of carbohydrate-processing enzymes. Oxford Molecular will use its software and discovery expertise to design multiple novel combinatorial libraries, which Cambridge Combinatorial will synthesize for screening by Cambridge Drug Discovery to identify potential drugs. Oxford Molecular and Cambridge Combinatorial have also agreed to provide consultancy services in information technology and combinatorial chemistry to Oxford GlycoScience.
Oxford Molecular and Oxford GlycoSciences Pen Research Agreement
Dec 21, 1998